Effects of imidazoline derivative RX871024 on insulin, glucagon, and somatostatin secretion from isolated perfused rat pancreas

I. B. Efanova, S. V. Zaitsev, A. M. Efanov, C. G. Östenson, A. Raap, H. J. Mest, P. O. Berggren, S. Efendić

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The effects of the imidazoline compound RX871024 on arginine-induced insulin, glucagon, and somatostatin secretion in the isolated perfused rat pancreas have been investigated. Arginine induced biphasic insulin, glucagon, and somatostatin release when infused for 20 min at 20 mM concentration and 3.3 mM glucose in the medium. RX871024, at 10 μM, did not influence basal hormone secretion but enhanced arginine-stimulated insulin and somatostatin release. In contrast, glucagon secretion was markedly inhibited by 10 μM imidazoline. RX871024 (1 μM) did not significantly affect arginine-induced insulin and somatostatin secretion but had an inhibitory effect on the second phase of glucagon release. In conclusion, RX871024 exerts a complex effect on the endocrine pancreas challenged by arginine, comprising stimulation of insulin and somatostatin release and inhibition of glucagon release. These effects on hormone release probably constitute the main mechanism of the antidiabetogenic action of the imidazolines.

Original languageEnglish
Pages (from-to)162-165
Number of pages4
JournalBiochemical and Biophysical Research Communications
Volume252
Issue number1
DOIs
StatePublished - Nov 9 1998
Externally publishedYes

Fingerprint

Imidazolines
Somatostatin
Glucagon
Arginine
Rats
Pancreas
Insulin
Derivatives
Biphasic Insulins
Hormones
Islets of Langerhans
2-(2-imidazolin-2-yl)-1-phenyl-1H-indole
Glucose

Keywords

  • Glucagon
  • Imidazoline
  • Insulin
  • Perfused rat pancreas
  • Somatostatin

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Cite this

Effects of imidazoline derivative RX871024 on insulin, glucagon, and somatostatin secretion from isolated perfused rat pancreas. / Efanova, I. B.; Zaitsev, S. V.; Efanov, A. M.; Östenson, C. G.; Raap, A.; Mest, H. J.; Berggren, P. O.; Efendić, S.

In: Biochemical and Biophysical Research Communications, Vol. 252, No. 1, 09.11.1998, p. 162-165.

Research output: Contribution to journalArticle

Efanova, I. B. ; Zaitsev, S. V. ; Efanov, A. M. ; Östenson, C. G. ; Raap, A. ; Mest, H. J. ; Berggren, P. O. ; Efendić, S. / Effects of imidazoline derivative RX871024 on insulin, glucagon, and somatostatin secretion from isolated perfused rat pancreas. In: Biochemical and Biophysical Research Communications. 1998 ; Vol. 252, No. 1. pp. 162-165.
@article{85ffba7fd84a422c8f167b53eff8adfe,
title = "Effects of imidazoline derivative RX871024 on insulin, glucagon, and somatostatin secretion from isolated perfused rat pancreas",
abstract = "The effects of the imidazoline compound RX871024 on arginine-induced insulin, glucagon, and somatostatin secretion in the isolated perfused rat pancreas have been investigated. Arginine induced biphasic insulin, glucagon, and somatostatin release when infused for 20 min at 20 mM concentration and 3.3 mM glucose in the medium. RX871024, at 10 μM, did not influence basal hormone secretion but enhanced arginine-stimulated insulin and somatostatin release. In contrast, glucagon secretion was markedly inhibited by 10 μM imidazoline. RX871024 (1 μM) did not significantly affect arginine-induced insulin and somatostatin secretion but had an inhibitory effect on the second phase of glucagon release. In conclusion, RX871024 exerts a complex effect on the endocrine pancreas challenged by arginine, comprising stimulation of insulin and somatostatin release and inhibition of glucagon release. These effects on hormone release probably constitute the main mechanism of the antidiabetogenic action of the imidazolines.",
keywords = "Glucagon, Imidazoline, Insulin, Perfused rat pancreas, Somatostatin",
author = "Efanova, {I. B.} and Zaitsev, {S. V.} and Efanov, {A. M.} and {\"O}stenson, {C. G.} and A. Raap and Mest, {H. J.} and Berggren, {P. O.} and S. Efendić",
year = "1998",
month = "11",
day = "9",
doi = "10.1006/bbrc.1998.9635",
language = "English",
volume = "252",
pages = "162--165",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Effects of imidazoline derivative RX871024 on insulin, glucagon, and somatostatin secretion from isolated perfused rat pancreas

AU - Efanova, I. B.

AU - Zaitsev, S. V.

AU - Efanov, A. M.

AU - Östenson, C. G.

AU - Raap, A.

AU - Mest, H. J.

AU - Berggren, P. O.

AU - Efendić, S.

PY - 1998/11/9

Y1 - 1998/11/9

N2 - The effects of the imidazoline compound RX871024 on arginine-induced insulin, glucagon, and somatostatin secretion in the isolated perfused rat pancreas have been investigated. Arginine induced biphasic insulin, glucagon, and somatostatin release when infused for 20 min at 20 mM concentration and 3.3 mM glucose in the medium. RX871024, at 10 μM, did not influence basal hormone secretion but enhanced arginine-stimulated insulin and somatostatin release. In contrast, glucagon secretion was markedly inhibited by 10 μM imidazoline. RX871024 (1 μM) did not significantly affect arginine-induced insulin and somatostatin secretion but had an inhibitory effect on the second phase of glucagon release. In conclusion, RX871024 exerts a complex effect on the endocrine pancreas challenged by arginine, comprising stimulation of insulin and somatostatin release and inhibition of glucagon release. These effects on hormone release probably constitute the main mechanism of the antidiabetogenic action of the imidazolines.

AB - The effects of the imidazoline compound RX871024 on arginine-induced insulin, glucagon, and somatostatin secretion in the isolated perfused rat pancreas have been investigated. Arginine induced biphasic insulin, glucagon, and somatostatin release when infused for 20 min at 20 mM concentration and 3.3 mM glucose in the medium. RX871024, at 10 μM, did not influence basal hormone secretion but enhanced arginine-stimulated insulin and somatostatin release. In contrast, glucagon secretion was markedly inhibited by 10 μM imidazoline. RX871024 (1 μM) did not significantly affect arginine-induced insulin and somatostatin secretion but had an inhibitory effect on the second phase of glucagon release. In conclusion, RX871024 exerts a complex effect on the endocrine pancreas challenged by arginine, comprising stimulation of insulin and somatostatin release and inhibition of glucagon release. These effects on hormone release probably constitute the main mechanism of the antidiabetogenic action of the imidazolines.

KW - Glucagon

KW - Imidazoline

KW - Insulin

KW - Perfused rat pancreas

KW - Somatostatin

UR - http://www.scopus.com/inward/record.url?scp=0032501150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032501150&partnerID=8YFLogxK

U2 - 10.1006/bbrc.1998.9635

DO - 10.1006/bbrc.1998.9635

M3 - Article

VL - 252

SP - 162

EP - 165

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 1

ER -